Histogenics Corp., of Waltham, Mass., said it priced an underwritten public offering of 26.15 million shares and warrants to purchase up to 19.61 million shares at a combined purchase price of 65 cents each. The gross proceeds are expected to be $17 million, and the company intends to use the net proceeds to complete the biologics license application submission relating to Neocart, an autologous neocartilage tissue implant that utilizes a patient's own cells to regenerate articular cartilage in the knee, and prepare for commercialization of the product following potential approval by the FDA.